Treatment for infant Acute Lymphocytic Leukemia

MISSION

To boost chemotherapy sensitivity and improve prognosis of infant t(4;11) pro-B-ALL patients through the increase of HDAC7 expression.

SECTOR

Therapeutics

STAGE

Preclinical assays

POTENTIAL INDICATIONS

- Infant t(4;11) pro-B-ALL with adverse prognosis
- Pro-B-ALL in adults with t(4;11)
- Other hematological malignancies (DLBCL...)



Dr Maribel Parra **Principal investigator**

Dr Oriol De Barrios

Senior researcher



TEAM



Mar Gusi-Vives **Predoctoral researcher**

Olga Collazo Lab technician

COLLABORATORS

Interfant consortium

Ronald W. Stam (Prinses Máxima Centrum, Netherlands) **Thomas Milne** (Oxford Univ., UK)

Giovanni Cazzaniga (University of Milan, Italy)

Pablo Menéndez (IJC, Barcelona)

THE PROBLEM

- t(4;11)-rearranged pro-B-ALL is a highly _ aggressive subtype of pro-B-ALL associated with a 35% of survival rate
- t(4;11) pro-B-ALL patients present _ chemoresistance to current treatment and usually relapse
- No other therapeutic options are available for these patients, particularly for infants under 1 year of age

COMPETITIVE ADVANTAGE

- New mechanism of action to improve survival
- Use of small molecules instead of/combined with conventional chemotherapy
- Potential to predict patients' survival depending on HDAC7 levels (codevelopment of diagnostic kit)

THE SOLUTION

- HDAC7 identified as a prognosis biomarker for t(4;11) pro-B-ALL infants
- Precise and combinatorial therapy for HDAC7 expression induction
- Two small molecule compounds: already tested in combination in vitro
- HDAC7 expression impairs t(4;11) pro-B-ALL cells' proliferation
- Promising results in the *in vivo* validation


ADDITIONAL INFO


- PCT patent filed (PCT/EP2022/087132) _
- Prestigious grants (DJCLS grant, Fight Kids Cancer, FIS, Gínjol-CERCA Agaur)
- Institut de Recerca contra la Leucèmia Josep Carreras
- Related publications: LINK _
- Contact: innovation@carrerasresearch.org





Figure 1. HDAC7 expression represents a clinical prognostic factor in t(4;11) pro-B-ALL. **Figure 2**. Preclinical efficiency, *in vitro* model.








Figure 2. Precise combinatorial therapy with HDAC7-induction capacity reduces t(4;11) pro-B-ALL cells viability. MTT assay to assess cell viability in SEM-K2 pro-B-ALL cells treated with Compound #1 (1 μ M, 6 days) and/or Compound #2 (1 μ M, 48 hours), or DMSO as control. Statistical significance is indicated as: * p < 0.05; **, p < 0.01; ***, p < 0.001; or n.s., non-significant.